-
Sector Analysis
Premature Labor (PL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Premature Labor (PL) Marketed and Pipeline Drugs Report Overview Premature/preterm labor (PL) is labor occurring after 20 and before 37 weeks gestation. Premature deliveries cause more than half of long-term morbidity and 75% of perinatal mortality. Premature labor is diagnosed primarily by history and symptoms. Symptoms of preterm labor include regular contractions before term gestational age associated with cervical change, pelvic pressure, menstrual-like cramps, watery vaginal discharge, and lower back pain. Although lower back pain is present in normal pregnancy as well,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PL-001 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PL-001 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PL-001 in Follicular Lymphoma Drug Details: PL-001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PL-001 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PL-001 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PL-001 in Diffuse Large B-Cell Lymphoma Drug Details: PL-001 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PL-001 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PL-001 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PL-001 in Primary Mediastinal B-Cell Lymphoma Drug Details: PL-001 is...
-
Product Insights
Pl Wind Farm
Pl Wind Farm is an Onshore Wind project located in Castile and León, Spain. The project is owned by Repsol Electricidad y Gas SA and is developed by Iberen Renovables SA; Repsol Electricidad y Gas SA. The project is at the permitting stage. Empower your strategies with our Pl Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business...
-
Product Insights
NewNet Present Value Model: Palatin Technologies Inc’s PL-9643
Empower your strategies with our Net Present Value Model: Palatin Technologies Inc's PL-9643 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Gefurulimab
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Gefurulimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PL-8177 in Ulcerative Colitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PL-8177 in Ulcerative Colitis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PL-8177 in Ulcerative Colitis Drug Details:PL-8177 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PL-3994 in Diastolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PL-3994 in Diastolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PL-3994 in Diastolic Heart FailureDrug Details:PL-3994 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Luveltamab Tazevibulin in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Luveltamab Tazevibulin in Peritoneal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Luveltamab Tazevibulin in Peritoneal Cancer Drug Details: STRO-002 is under development...